Teva’s EVP of R&D to Outline Growth Strategy at BofA Conference
Event summary
- Teva’s EVP of Global R&D & Chief Medical Officer, Eric Hughes, will present at the BofA Securities Health Care Conference on May 12, 2026.
- The presentation is scheduled for 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).
- Live webcasts will be available on Teva’s Investor Relations website, with archived versions accessible for 30 days post-event.
- Teva is positioning itself as a leading innovative biopharmaceutical company, supported by a generics business.
The big picture
Teva’s presentation at the BofA Securities Health Care Conference comes amid its broader transformation into an innovative biopharmaceutical company. The event provides a platform for Teva to articulate its strategic vision, particularly in neuroscience and immunology, against a backdrop of intense competition and financial constraints. Investors will be watching closely to see how Teva plans to navigate these challenges while maintaining profitability in its generics business.
What we're watching
- Execution Risk
- How Teva will balance its Pivot to Growth strategy with its significant indebtedness and competitive pressures.
- Pipeline Progress
- Whether Teva can successfully develop and commercialize additional pharmaceutical products to sustain growth.
- Market Positioning
- The pace at which Teva can expand its innovative and biosimilar medicines pipeline to compete effectively.
Related topics